Clinical Trials
25 trialsNCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT05363488 2023-04-03
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Pfizer
Completed
NCT02287233 2022-08-29
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
AbbVie
Phase 1/2 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT00718159 2019-01-10
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Eli Lilly and Company
Phase 1 Completed
NCT01602952 2018-08-29
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Il-Yang Pharm. Co., Ltd.
Phase 1/2 Completed
NCT01994837 2018-06-06
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 2 Completed
NCT02098967 2018-05-17
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
Hoffmann-La Roche
Phase 1 Completed
NCT00822094 2017-11-24
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Jazz Pharmaceuticals
Phase 2 Completed
NCT01380756 2017-11-06
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Amgen
Phase 1 Completed
NCT01677780 2017-07-07
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Hoffmann-La Roche
Phase 1 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT00034684 2015-06-17
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT00030186 2012-08-23
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00497991 2010-12-08
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
AstraZeneca
Phase 1 Completed
NCT00512083 2009-09-25
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Antisoma Research
Phase 2 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed
NCT00129168 2008-04-01
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Kanisa Pharmaceuticals
Phase 1/2 Completed
NCT00233909 2008-04-01
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Kanisa Pharmaceuticals
Phase 1/2 Completed